Video

AI, Antigen Selection, & Agile Regulation: A Long Road Ahead

Source: Advancing RNA

Navigating antigen selection for personalized mRNA cancer immunotherapies is a major challenge for industry and regulators. In this clip, CureVac’s Ulrike Jägle articulates why the integration of AI/ML into clinical development presents a significant and ongoing regulatory hurdle.

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Advancing RNA? Subscribe today.

Subscribe to Advancing RNA X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Advancing RNA

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)